Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Purchases 16,692 Shares

Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc acquired 16,692 shares of the company's stock in a transaction that occurred on Thursday, December 26th. The stock was purchased at an average price of $14.38 per share, for a total transaction of $240,030.96. Following the purchase, the director now owns 14,720,931 shares of the company's stock, valued at $211,686,987.78. The trade was a 0.11 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Tuesday, December 24th, Ecor1 Capital, Llc acquired 11,958 shares of Zymeworks stock. The stock was purchased at an average cost of $14.12 per share, with a total value of $168,846.96.

Zymeworks Price Performance

Shares of ZYME stock remained flat at $14.50 on Friday. The company had a trading volume of 461,479 shares, compared to its average volume of 609,735. Zymeworks Inc. has a one year low of $7.97 and a one year high of $17.70. The firm has a market cap of $998.73 million, a P/E ratio of -9.67 and a beta of 1.12. The company has a 50-day simple moving average of $14.25 and a 200 day simple moving average of $12.00.

Zymeworks (NYSE:ZYME - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01. The business had revenue of $16.00 million during the quarter, compared to analyst estimates of $17.90 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. Zymeworks's revenue for the quarter was down 3.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.41) earnings per share. On average, analysts predict that Zymeworks Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ZYME shares. JPMorgan Chase & Co. upgraded shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 target price for the company in a research note on Monday, December 16th. HC Wainwright reiterated a "neutral" rating and issued a $12.00 price objective on shares of Zymeworks in a research note on Friday, November 22nd. Leerink Partners raised shares of Zymeworks from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $10.00 to $25.00 in a report on Thursday, November 7th. Leerink Partnrs raised Zymeworks from a "hold" rating to a "strong-buy" rating in a report on Thursday, November 7th. Finally, Stifel Nicolaus boosted their price objective on Zymeworks from $21.00 to $28.00 and gave the company a "buy" rating in a research note on Monday, October 28th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Zymeworks has an average rating of "Moderate Buy" and an average target price of $19.17.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP lifted its stake in Zymeworks by 12.7% during the second quarter. Rubric Capital Management LP now owns 3,917,331 shares of the company's stock worth $33,336,000 after purchasing an additional 441,947 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Zymeworks by 0.8% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,945,491 shares of the company's stock valued at $24,416,000 after buying an additional 14,604 shares in the last quarter. Perceptive Advisors LLC lifted its position in Zymeworks by 55.2% in the 2nd quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company's stock worth $14,192,000 after buying an additional 592,904 shares during the last quarter. State Street Corp boosted its stake in Zymeworks by 6.1% in the third quarter. State Street Corp now owns 1,171,777 shares of the company's stock worth $14,706,000 after buying an additional 67,401 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Zymeworks by 127.5% during the second quarter. Dimensional Fund Advisors LP now owns 715,632 shares of the company's stock valued at $6,090,000 after acquiring an additional 401,068 shares during the last quarter. Institutional investors own 92.89% of the company's stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.